Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This is a single arm prospective pilot trial that evaluates the ability of a novel imaging
agent (68Ga-FAP-2286) to identify pathologic fibrosis in the setting of hepatic, cardiac and
pulmonary fibrosis.
FAP-2286 is a peptide that potently and selectively binds to Fibroblast Activation Protein
(FAP). FAP is a transmembrane protein expressed on fibroblasts and has been shown to have
higher expression in idiopathic pulmonary fibrosis (IPF), cirrhosis, and cardiac fibrosis.